← Issue №7/ week of Aug 16, 2026/Hepatology

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis.

From GI Signals issue №7: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · Aug 17, 2026 · Aliment Pharm Ther · IF 6.7

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis.

EpidemiologyPSCcirrhosis
Clinical takeawayAsk PSC patients systematically about pruritus; 38% report moderate-to-severe symptoms strongly associated with cirrhosis and cholestasis markers. Assess using validated scales (WI-NRS, 5-D Itch scale) and recognize pruritus as an indicator of disease severity and quality-of-life burden. No new therapies identified, but findings underscore the existing treatment gap.
What it found38% of PSC patients report moderate-to-severe pruritus (WI-NRS ≥ 4) over 6 months, correlating with cirrhosis (p=0.01), alkaline phosphatase elevation (p=0.0001), bilirubin elevation (p=0.0006), and low albumin (p=0.01); 86.5% of those with recent moderate-to-severe itch experienced severe itch at least once during 6-month follow-up.
ContextConfirms pruritus as a major symptom burden in PSC and establishes specific prevalence (38% moderate-to-severe over 6 months) and quality-of-life impact (SF-36 correlation -0.47). Identifies cirrhosis and cholestasis markers as correlates of severity but does not propose new interventions.
Emergingsuggested applicable standard· American College of Gastroenterology (Kwo PY, Cohen SM, Lim JK), "ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries," Am J Gastroenterol 2017;112(1):18-35

Decision at stakewhether to systematically assess and monitor pruritus severity in patients with confirmed primary sclerosing cholangitis

Patients with an elevated ALP, with or without elevated bilirubin, should also be tested for primary sclerosing cholangitis with cholangiography by MRCP (or ERCP) together with serum IgG4, because some extrahepatic cholestatic disease (e.g., PSC, HIV/AIDS cholangiopathy) may not be visible on ultrasound; a history of cholangitis or of colonic inflammatory bowel disease further raises suspicion but is not a prerequisite for obtaining cholangiography.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

An elevated alkaline phosphatase should first be confirmed to be of hepatic origin: confirm with an elevated GGT, or use ALP isoenzyme fractionation or 5'-nucleotidase to separate liver from non-hepatic (e.g., bone) sources. GGT should NOT be used as a standalone screening test in the absence of otherwise-abnormal liver chemistries, and GGT is not specific (elevated in >50% of alcohol users without overt liver disease). Patients with an elevated ALP, with or without elevated bilirubin, should be tested for primary biliary cholangitis with an anti-mitochondrial antibody (AMA). Once ALP is confirmed to be of hepatic origin, obtain a liver ultrasound to assess the hepatic parenchyma and bile ducts: biliary dilatation suggests an extrahepatic cause, while a non-dilated biliary system suggests an intrahepatic cause. Patients with an elevated ALP, with or without elevated bilirubin, should also be tested for primary sclerosing cholangitis with cholangiography by MRCP (or ERCP) together with serum IgG4, because some extrahepatic cholestatic disease (e.g., PSC, HIV/AIDS cholangiopathy) may not be visible on ultrasound; a history of cholangitis or of colonic inflammatory bowel disease further raises suspicion but is not a prerequisite for obtaining cholangiography. Liver biopsy is generally not required; about 80% of isolated ALP elevations can be diagnosed from history, physical exam, routine labs, and chest X-ray.

American College of Gastroenterology (Kwo PY, Cohen SM, Lim JK), "ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries," Am J Gastroenterol 2017;112(1):18-35 · reviewed 2026-07-23 ↗
Dean R … Bowlus CL · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №7 Every paper GI Signals surfaces gets a page like this one. All issues